Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854528 | 1.00 | PPARG (0.40) | PPARGALDH1A1PPARAPLGPRSS1 | |
| SCHEMBL2851732 | 0.92 | PPARG (0.41) | PPARGPPARA | |
| SCHEMBL2851730 | 0.92 | PPARG (0.41) | PPARGPPARA | |
| SCHEMBL2859244 | 0.92 | PPARG (0.40) | PPARGPPARA | |
| SCHEMBL2859247 | 0.92 | PPARG (0.40) | PPARGPPARA | |
| SCHEMBL2854965 | 0.91 | PPARG (0.41) | PPARGALDH1A1PPARA | |
| SCHEMBL2854968 | 0.91 | PPARG (0.41) | PPARGALDH1A1PPARA | |
| SCHEMBL2854262 | 0.91 | FPR2 (0.41) | PPARGALDH1A1PLGPRSS1PRSS2 | |
| SCHEMBL2854258 | 0.91 | FPR2 (0.41) | PPARGALDH1A1PLGPRSS1PRSS2 | |
| SCHEMBL2857208 | 0.90 | PPARG (0.40) | PPARGPPARAPLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | claimed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | claimed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | claimed |
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
| EP-1575911-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004046091-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885ALDH1A1 531/4885PPARA 2/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PPARG 1/4885ALDH1A1 531/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.